US0352551081
US0352551081
Anika Therapeutics Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 262.04M EUR | 194.66M EUR | 193.68M EUR | 133.47M EUR |
Enterprise Value | 244.19M EUR | 181.5M EUR | 178.39M EUR | 102.24M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 20.61x | -- | -- | -- |
Price to Sales | 2.17x | 1.61x | 1.67x | 1.54x |
Price to Book | 1.91x | 1.42x | 1.45x | 0.93x |
EV/Revenue | 2.02x | 1.5x | 1.53x | 1.18x |
EV/EBITDA | 80.33x | 354.49x | -- | -- |
Price to FCF (P/FCF) | 85.57x | 346.37x | 186.41x | 18.24x |
EV/FCF | 79.74x | 322.95x | 171.7x | 13.97x |
FCF Yield | 1.17% | 0.29% | 0.54% | 5.48% |